Concise biotech intelligence. Oncology, cell therapy, antibodies, ADCs, gene therapy, and early clinical signals. High signal, low noise.
Joined November 2025
- Tweets2.3K
- Following7
- Followers1.1K
- Likes562
BioSignal retweeted
Cellectis exits internal allo CAR-T and pivots to in vivo base and epigenetic editing for dyslipidemias
In June the FDA gave Cellectis' lasme-cel RMAT designation. The pivotal B-ALL trial had an interim analysis guided for Q4. On Monday Cellectis walked away from it.
The company is exiting lasme-cel and eti-cel, its two off-the-shelf CAR-Ts, and looking for partners to take them. Its reasons: better frontline regimens mean fewer relapses, and bispecifics plus in vivo CAR-T now crowd the later lines. Enrollment slowed. The stock traded down about a third on Nasdaq that day.
I posted the RMAT in June with the AstraZeneca angle, since AZ took roughly 44% of Cellectis in 2024. Three months later, the company whose UCART19 opened the off-the-shelf CAR-T field in 2015 no longer wants to carry one to approval.
What it is moving to is a tougher race. HEAL-101 is a TALE base editor against APOC3, in LNP, given once by IV, for severe hypertriglyceridemia. HEAL-201 is a TALE epigenetic editor aimed at the PCSK9 promoter. Both start as investigator-initiated trials in China, with first data guided for H2 2027 and H1 2028.
Look at who is already in that lane. Ionis' olezarsen won FDA approval in severe hypertriglyceridemia on June 24. Arrowhead's plozasiran cut median triglycerides 79% and 81% at month 12 in SHASTA-3 and SHASTA-4 and plans to file before year-end. Lilly bought Verve for its PCSK9 base editor. And Shanghai's CorrectSequence dosed an APOC3 base editor in a Chinese IIT in October 2025.
So HEAL-101 arrives as a one-time edit against an approved drug, a second RNA drug heading to filing, and a Chinese editor that has been in patients for almost a year. The argument that can win is durability: one infusion against a lifetime of injections. Proving that takes years of follow-up, which a first readout in 2027 cannot show.
Runway now reaches H2 2028 after headcount cuts the company did not size. Allogene, a Cellectis partner still running its pivotal ALPHA3 trial, is now the most visible listed name carrying the allogeneic thesis Cellectis just dropped.
$CLLS $AZN $IONS $ARWR $LLY $ALLO $XBI $IBB
✨ Made with AI
BioSignal retweeted
Dexmedetomidine sublingual film selective alpha-2 agonist that cut acute agitation within 2 hours. It has to be given under supervision by a healthcare professional, which confines an acute-agitation drug to the ER and the inpatient ward. Acute agitation mostly happens at home.
Teva bid for BioXcel's neuroscience assets on the same day BioXcel filed Chapter 11 in Delaware. $57.5 million upfront, up to $67.5 million in development milestones, and up to $20 million more tied to sales.
Read the milestone structure, because that is the actual trade. The development payments are indexed to the outcome and the timing of one pending sNDA: at-home use of BXCL501, PDUFA date 14 November. Approve on schedule and the estate collects the top of the ladder. Slip, and the estate collects less for the same approval.
I have not seen a bankruptcy auction price an FDA calendar this directly. Creditor recovery is now partly a function of whether the agency hits its own date.
The asset itself is not a failure. Igalmi cleared in 2022 on two Phase 3s, dexmedetomidine sublingual film, a selective alpha-2 agonist that cut acute agitation within two hours. The problem was always the label. It has to be given under supervision by a healthcare professional, which confines an acute-agitation drug to the ER and the inpatient ward. Acute agitation mostly happens at home.
BioXcel ran out of runway before it could reach the label that made the product make sense. $12.8 million in cash at the end of June against roughly $6 million a quarter in operating burn. Shares fell more than 70% to about nineteen cents.
Teva closed a deal for Emalex in June worth up to $900 million. This is the same neuroscience pivot at a seventh of the headline, because this seller had no time left.
One caveat worth holding. Teva is the stalking horse, not the buyer. The auction can still take it away from them.
$TEVA $BTAI $XBI $IBB
✨ Made with AI
BioSignal retweeted
This is the kind of breakdown that makes a complicated deal actually easy to follow. The milestone structure is especially interesting
BioSignal retweeted
2026年8月2日、FDAがfirst-in-human試験の前には求めないCMC作業を1つの表にまとめて公開したことが、BioSignalのXポストで紹介されました。対象は、CDER規制の遺伝子組換えバイオ医薬品に係る初回のPhase 1 INDです。
xitter.gq/BioSignal/status/20840…
The FDA has published, in one table, the CMC work it does not expect before a first-in-human trial. Read the table, then read why it exists.
For an original Phase 1 IND covering a CDER-regulated recombinant biologic, FDA says it does not expect a two-tier cell bank, a clonally derived cell bank, a cell-based potency assay reflective of mechanism, method validation results, an extractables and leachables evaluation, a two-tier reference standard system, or product-specific viral clearance where prior knowledge can be leveraged. Stability: one month from a representative lot, where no degradation is observed.
One month. FDA estimates sponsors can cut application development time by up to 12 months.
Now the why, which HHS put in writing in the Operation TrialBlazer roadmap. China's discovery-to-IND cycles run 50% to 70% faster than the rest of the world. In the US, the gap between requesting a pre-IND meeting and submitting the IND averages 380 days, with a range approaching 700. IRB approval and contract negotiation can add up to 13 months of further delay. China requires sponsors to commit to starting the trial within 12 weeks of filing.
In 2024 China registered more clinical trials than the US, over 7,100, or 39% of the global total. In 2025 global companies spent over $137B licensing China-based assets. HHS projects Chinese-developed drugs will account for 35% of FDA approvals by 2040.
Both agencies call this a clarification. Read it as what it is: a regulator publishing its own competitive threat assessment, then removing the friction it had just finished measuring.
The speed gap is why a large share of the licensing deals of the last three years happened at all. Washington has now said out loud that it intends to narrow it.
$IQV $MEDP $2359 HK $XBI $IBB
✨ Made with AI
BioSignal retweeted
Targeting needs to be further refined if we want to induce long term responses. Quality over quantity
BioSignal retweeted
@idorsia for vitiligo also... Just FYI 😁
Early but possible...
BioSignal retweeted
A therapy can be scientifically successful and commercially unsuccessful at the same time. Cell therapy keeps reminding us of that.
BioSignal retweeted
基因治疗，罕见病，即使获批，后续的商业化是个大问题
Another China gene-therapy IPO filing. Usually I skim the prospectus and move on. This one stopped me — because of what the founder signed.
Shanghai VitalGen (天泽云泰) just cleared the first gate for a STAR Market listing. Pre-revenue, listing under Standard 5, three straight years of 200M+ RMB net losses, working-capital risk flagged in its own prospectus. A standard China-biotech-in-a-capital-winter story — until you read the lock-up.
Founder Zhao Xiaoping bolted a triple, performance-linked extension onto her own share lock-up. On top of the statutory 3 years, she adds another 12 months for each of: no approved drug by end-2027; under 300M RMB cumulative BD/licensing revenue across 2027-2029; no profitable year by 2030. Hit all three and she's locked for ~6 years. A founder pricing her own liquidity to the pipeline actually landing.
So what's the pipeline?
VGR-R01 — the world's first in-clinic gene therapy for Bietti crystalline dystrophy, an inherited blinding disease common in East Asians that Western pharma never touched. Breakthrough-designated in China, I/II complete, patients posting vision gains. No Western competitor, because the West skipped the indication.
VGN-R09b — China's first homegrown AAV gene therapy for AADC deficiency and Parkinson's, the same intraputaminal AAV-AADC approach as PTC's Upstaza/Kebilidi. PTC owns that mechanism in the US and EU but doesn't sell it in China. VitalGen is moving into that gap on home turf.
Underneath both sits a Cas12b editing platform — the third class of mammalian genome editor after Cas9 and Cas12a — plus in-house AAV and LNP delivery.
The read for Western desks: China is productizing the rare-disease gene-therapy indications the West deprioritized, and a founder is staking six years of her own liquidity on it landing. Watch the China flank on $PTCT — and whether Standard-5 IPOs are reopening for gene therapy.
$PTCT $CRSP $XBI $IBB
✨ Made with AI
BioSignal retweeted
The RMAT designation matters beyond the headline — it gives Cellectis intensive FDA interaction and rolling review. The real question for lasme-cel is whether allogeneic persistence is durable enough vs autologous. Early B-ALL data looks promising but longer follow-up is the test.
BioSignal retweeted
Truly appreciate your works, BioSignal. Your summaries are valuable to biotech community. However the info here requires your attention - Tang Prize has no connection with China. The sponsor, Dr. Samuel Yin who just passed away a few weeks ago, is a philanthropist from Taiwan
BioSignal retweeted
But Zepzelca didn´t fail in his trial in 1L of #SCLC. The first line is more important than 2L. And, you have to read that Zepzelca got a good result (as expected), the Topotecan got the best results in his history that is very rare.
BioSignal retweeted
And to add something else, in terms of safety, Zepzelca is significantly safer than the Topo. And that's something oncologists know from real-world experience.
BioSignal retweeted
Ex-vivo CAR-T is officially on borrowed time. The holy grail of cell therapy is in vivo—reprogramming T-cells directly inside the patient's body using mRNA-LNPs—and a dark-horse Chinese biotech just proved it works in humans.
Traditional CAR-T ($GILD, $BMY) remains a manufacturing and clinical nightmare. It requires weeks of ex-vivo editing, costs $400k+, and forces patients through toxic lymphodepletion. In vivo CAR-T turns the patient into the factory, expressing CAR receptors within hours via a simple IV infusion with no pre-conditioning required.
At ASCO 2026, private Chinese player WestGene Biopharma dropped breakthrough first-in-human data for WGb-0301, their CD8-targeted mRNA-LNP in vivo CAR-T:
• 100% CAR expression inside r/r B-cell lymphoma patients within 4-6 hours.
• Deep B-cell depletion achieved, including 1 Complete Response (CR).
• Zero Grade 3+ treatment-related AEs.
• Successfully redosed up to 10 times with zero efficacy decay—a feat impossible with traditional cell therapies.
The global validation came immediately. Nasdaq-listed Cartesian Therapeutics ($RNAC) just locked in a strategic out-licensing deal to use WestGene’s tLNP platform. They are targeting the massive autoimmune market, launching a BCMA in vivo CAR-T for generalized myasthenia gravis (gMG). Clinical trials start H2 2026, with data dropping H1 2027.
Big Pharma is desperate for clinically validated in vivo delivery platforms. WestGene's human data moves them to the front of the pack, and $RNAC just secured a massive tech upgrade to challenge the auto-immune cell therapy space.
This is the pipeline paradigm shift to watch. 🧵
$RNAC $GILD $BMY $SANA $XBI $IBB